Jake R. Nunn, MBA

Jake R. Nunn, MBA is a Director of the Company and Chairman of the Compensation Committee.  Mr. Nunn has over 30 years of experience in the life science industry as an investor, independent director, research analyst and investment banker.  He is currently a partner at SR One Capital Management and an advisor to life science companies.  Previously he was a venture advisor at New Enterprise Associates (NEA), where he was a partner from 2006 to 2018, focusing on later-stage specialty pharmaceuticals and biotech, and managing several of NEA’s public investments in healthcare.  Mr. Nunn is currently a Director of Addex Therapeutics (Nasdaq, SIX: ADXN) and Zenas BioPharma (Nasdaq: ZBIO).  He previously was a Director of Regulus Therapeutics (acquired by Novartis), Dermira Inc. (acquired by Eli Lilly), Hyperion Therapeutics (acquired by Horizon Pharma PLC), TriVascular (acquired by Endologix), Aciex Therapeutics (acquired by Nicox SA), Transcept Pharmaceuticals (merged with Paratek) and a board observer at Vertiflex, Inc. (acquired by Boston Scientific).  Prior to NEA, Mr. Nunn worked at MPM Capital as a partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing.  Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments.  Mr. Nunn was also an investment banker with Alex. Brown & Sons.  He received an MBA degree from the Stanford Graduate School of Business and an A.B. degree in Economics from Dartmouth College.  Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors’ Consortium executive education program.

Mr. Nunn has served as a member of the Board of Directors since 2022.